Relay Therapeutics Inc. (RLAY): Price and Financial Metrics


Relay Therapeutics Inc. (RLAY): $36.74

-0.14 (-0.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RLAY POWR Grades


  • Growth is the dimension where RLAY ranks best; there it ranks ahead of 74.32% of US stocks.
  • The strongest trend for RLAY is in Momentum, which has been heading down over the past 48 weeks.
  • RLAY's current lowest rank is in the Momentum metric (where it is better than 9.5% of US stocks).

RLAY Stock Summary

  • Relay Therapeutics Inc's stock had its IPO on July 16, 2020, making it an older stock than merely 1.01% of US equities in our set.
  • With a price/sales ratio of 40.48, Relay Therapeutics Inc has a higher such ratio than 94.03% of stocks in our set.
  • Over the past twelve months, RLAY has reported earnings growth of 351.01%, putting it ahead of 93.12% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Relay Therapeutics Inc, a group of peers worth examining would be OLED, DBX, SRNE, CREE, and PZG.
  • Visit RLAY's SEC page to see the company's official filings. To visit the company's web site, go to relaytx.com.

RLAY Valuation Summary

  • RLAY's price/sales ratio is 35.2; this is 210.13% higher than that of the median Healthcare stock.
  • Over the past 14 months, RLAY's EV/EBIT ratio has gone up 20.
  • Over the past 14 months, RLAY's price/earnings ratio has gone up 24.8.

Below are key valuation metrics over time for RLAY.

Stock Date P/S P/B P/E EV/EBIT
RLAY 2021-08-31 35.2 4.8 -7.2 -11.5
RLAY 2021-08-30 32.9 4.5 -6.7 -10.8
RLAY 2021-08-27 32.9 4.5 -6.7 -10.7
RLAY 2021-08-26 32.7 4.5 -6.7 -10.7
RLAY 2021-08-25 32.9 4.5 -6.7 -10.8
RLAY 2021-08-24 34.1 4.7 -7.0 -11.2

RLAY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RLAY has a Quality Grade of C, ranking ahead of 52.81% of graded US stocks.
  • RLAY's asset turnover comes in at 0.111 -- ranking 258th of 677 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows RLAY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.111 1 -0.620
2021-03-31 0.125 1 -0.215
2020-12-31 0.146 1 -0.191

RLAY Price Target

For more insight on analysts targets of RLAY, see our RLAY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $54.33 Average Broker Recommendation 1.43 (Moderate Buy)

RLAY Stock Price Chart Interactive Chart >

Price chart for RLAY

RLAY Price/Volume Stats

Current price $36.74 52-week high $64.37
Prev. close $36.88 52-week low $26.44
Day low $36.18 Volume 452,700
Day high $37.11 Avg. volume 639,010
50-day MA $33.30 Dividend yield N/A
200-day MA $37.43 Market Cap 3.41B

Relay Therapeutics Inc. (RLAY) Company Bio


Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.


RLAY Latest News Stream


Event/Time News Detail
Loading, please wait...

RLAY Latest Social Stream


Loading social stream, please wait...

View Full RLAY Social Stream

Latest RLAY News From Around the Web

Below are the latest news stories about Relay Therapeutics Inc that investors may wish to consider to help them evaluate RLAY as an investment opportunity.

Relay Therapeutics to Present Clinical Data on RLY-4008 and Preclinical Data on RLY-2608 at AACR-NCI-EORTC Molecular Targets Conference

Relay Therapeutics to host a conference call on October 8th at 12:30 pm E.T.CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced that initial clinical data for RLY-4008 and preclinical data for RLY-2608 have been selected for a plenary oral and poster presentation, respectively, at the u

Yahoo | September 13, 2021

Time To Worry? Analysts Are Downgrading Their Relay Therapeutics, Inc. (NASDAQ:RLAY) Outlook

The analysts covering Relay Therapeutics, Inc. ( NASDAQ:RLAY ) delivered a dose of negativity to shareholders today, by...

Yahoo | August 18, 2021

Relay Therapeutics, Inc. (NASDAQ:RLAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

It's shaping up to be a tough period for Relay Therapeutics, Inc. ( NASDAQ:RLAY ), which a week ago released some...

Yahoo | August 15, 2021

Relay Therapeutics Announces Corporate Updates and Reports Second Quarter 2021 Financial Results

Company selected RLY-2608 as PI3Kα mutant inhibitor development candidate and plans to initiate first-in-human study in the first half of 2022 RLY-2608 potently inhibits mutants H1047X, E542X, and E545X, which affect over 100,000 patients annually in the U.S. Relay Therapeutics and EQRx enter a collaboration to discover, develop, and commercialize novel oncology medicines CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medic

Yahoo | August 12, 2021

Relay Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Highlights

CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, plans to report second quarter 2021 financial results after the close of market on Thursday, August 12, 2021. The company will not be conducting a teleconference in conjunction with its financial results press release. About Relay TherapeuticsRelay The

Yahoo | August 5, 2021

Read More 'RLAY' Stories Here

RLAY Price Returns

1-mo 23.50%
3-mo 2.31%
6-mo 12.98%
1-year -6.75%
3-year N/A
5-year N/A
YTD -11.60%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7694 seconds.